Granules India Limited (GRANULES) announced potential first-to-file status for its Ruxolitinib Extended-Release Tablets ANDA, aiming for 180 days of generic.
Granules India Limited (GRANULES) stock is down 5% intraday at ₹829.1, showing retracement post-breakout gains.
Granules India Limited (GRANULES) reports Q1 FY27 results with revenue up 22% YoY, EBITDA up 37%, and PAT up 60%.
Granules India Limited (GRANULES) secures Sole First-to-File status for its ANDA for Sodium Oxybate Extended-Release for Oral Suspension.
Granules India Limited (GRANULES) announced its USFDA EIR for Chantilly Facility with a Voluntary Action Indicated (VAI) classification.